Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
about
Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.Pharmacokinetic/ pharmacodynamic-driven drug developmentPhysiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.Application of physiologically based pharmacokinetic models in chemical risk assessment.Physiologically based pharmacokinetics (PBPK).The future of toxicity testing.An update on computational oral absorption simulation.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.PBPK modeling of irbesartan: incorporation of hepatic uptake.Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes.Incorporating Human Dosimetry and Exposure Information with High-Throughput Screening Data in Chemical Toxicity AssessmentPhysiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
P2860
Q30837825-07EEE413-6FD3-4BD3-BBFD-01301DFB37CCQ34051505-68A32D63-5DDB-4C16-A1B2-EBF43CFE9829Q35054518-6DB19520-4466-4554-B1E7-C55DF8FBA782Q35864986-15BABC3C-F389-47CF-B133-5AAFC06F9388Q37550553-DCBD9A1D-986F-4C85-8DEA-467C0A394AA1Q37767386-D42BA067-6D0F-406F-9F93-3F982E534838Q37937047-CB7430A5-C692-4FB3-80AA-FA6113948FAFQ37960638-35038D6C-E511-4111-AA33-2FDBE331CBABQ37965706-229F63F5-3432-42AA-AD2A-E5CC43EF2401Q37974113-AA7A6F02-8C62-45EF-939A-4FDF38F00636Q38016204-CFB28102-4DFF-4A40-9C76-41B791F9A2E1Q38087695-5636916B-3D56-4B89-813A-0EF8C8C74687Q39604949-D581CF75-DCA6-484E-A8A8-536BC21C801BQ40875739-36256870-52DE-4A28-9074-7291B85F5FB8Q42966822-0C9B54B3-1400-4A89-8034-8871D20E9D0EQ45196773-C8BBE01A-D940-4542-9BAC-F6E10C33FDCFQ57543212-CE803C85-E947-4B5F-B4F7-0B71DBC44200Q57684574-B812698E-D611-400E-85A9-C859633589DA
P2860
Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Physiologically based approach ...... n vitro-in vivo extrapolation.
@en
Physiologically based approach ...... n vitro-in vivo extrapolation.
@nl
type
label
Physiologically based approach ...... n vitro-in vivo extrapolation.
@en
Physiologically based approach ...... n vitro-in vivo extrapolation.
@nl
prefLabel
Physiologically based approach ...... n vitro-in vivo extrapolation.
@en
Physiologically based approach ...... n vitro-in vivo extrapolation.
@nl
P2860
P356
P1476
Physiologically based approach ...... n vitro-in vivo extrapolation.
@en
P2093
Claire E Mackie
Stefan S De Buck
P2860
P304
P356
10.1517/17425255.3.6.865
P407
P577
2007-12-01T00:00:00Z